Patient-friendly summary
If you read nothing else
Bottom line
Fibromyalgia diagnostic criteria have evolved from a tender-point pain model (1990) to a multi-symptom model (2010 and the 2011/2016 proposals), but no objective marker exists yet, and clinician dissatisfaction, misdiagnosis, sex-ratio bias, and under-recognition of biopsychosocial factors persist.
Moderate evidencePublished
Evidence hierarchy
Study participants
Adults with fibromyalgia syndrome; pediatric population excluded.
Full research — for clinicians and curious readers
Study Summary
This narrative review traces the historical development and critical evaluation of diagnostic criteria for fibromyalgia syndrome (FMS), focusing on the American College of Rheumatology (ACR) criteria of 1990, 2010, and the later 2011 and 2016 proposals. The authors describe the shift from a tender-point-based pain syndrome (1990) toward a multi-symptom construct measured by the Widespread Pain Index (WPI) and Symptom Severity (SS) Scale, and discuss derived tools such as the Polysymptomatic Distress Scale and the FMS Survey Questionnaire. They review how prevalence and the female-to-male ratio change with the criteria used, examine differential diagnosis and comorbidity, and outline newer proposals (the AAPT dimensional model and central-sensitization markers such as slowly repeated evoked pain). The review concludes that despite the official 2010 criteria and the 2011/2016 proposals, complaints from clinicians and patients persist, misdiagnosis remains common, and psychological, environmental, and sociocultural factors are insufficiently recognized.
Key Findings
| Finding | Detail | Impact |
|---|---|---|
| Fibromyalgia diagnosis shifted from a tender-point pain syndrome to a multi-symptom disorder | The 1990 ACR criteria required pain at 11 of 18 tender points plus widespread pain for at least 3 months; the 2010 criteria replaced tender points with the Widespread Pain Index (WPI, 0-19) and Symptom Severity Scale (SS, 0-12), diagnosing FMS when WPI >=7 and SS >=5, or WPI 3-6 and SS >=9, with symptoms present for at least 3 months. | High |
| The female-to-male sex ratio varies markedly depending on the criteria applied | A female-to-male ratio of 13.7:1 was observed with the 1990 ACR criteria, 4.8:1 with the 2010 criteria, and 2.3:1 with the 2011 proposal; tender-point exams appear biased toward women, and the article cites studies finding the female proportion was <=60% with unbiased patient selection. | High |
| Prevalence estimates differ by criteria and population | FMS prevalence is estimated at 2%-4% in the general population (around 2.45% in Spain per the 2016 EPISER study); prevalence is higher when the 2010 criteria are used and reaches 5.4% with the self-administered 2011 criteria. | Medium |
| Reported validity is high but varies across criteria and populations | Sensitivity/specificity for distinguishing FMS from other rheumatic conditions was 88.4%/81.1% (1990 criteria) and 96.6%/91.8% (2010 criteria, vs RA and OA); in Spanish samples the 2010 criteria showed 85.6%/73.2%; the 2011 criteria showed 88.3% sensitivity / 91.8% specificity vs healthy controls in Spanish samples and 64%/96% in a Japanese sample vs RA/OA. | Medium |
| The 2016 proposal reduced misclassification of regional pain as FMS and removed exclusion-based diagnosis | Requiring generalized pain in at least 4 of 5 regions lowered the misclassification rate from 1.8% (widespread anterior pain criterion) to 0.4%; the 2016 proposal also states that an FMS diagnosis is valid irrespective of, and does not exclude, other clinically important illnesses. | High |
| Comorbidity is common and current criteria do not require excluding other conditions | The authors note FMS frequently coexists with other rheumatic diseases and chronic overlapping pain conditions and mental disorders; Wolfe et al. indicate exclusionary tests are not needed and FMS remains a valid construct irrespective of comorbid diagnoses, though in practice diagnosis often still rests on excluding similar diseases. | Medium |
| Central-sensitization markers may improve diagnostic accuracy in the future | Slowly repeated evoked pain (SREP) gave a global diagnostic accuracy of 85.4% (FMS vs healthy) and 87.7% (FMS vs RA); combining SREP with fatigue and insomnia reportedly reached 99% global accuracy (98% sensitivity, 100% specificity) in a recent study, though such markers are not yet in routine use. | Medium |
| Misdiagnosis and lack of consensus persist despite official criteria | Most clinicians reportedly continue to use digital palpation and clinical judgment rather than systematically applying any ACR criteria, contributing to over- and under-diagnosis; the authors also stress that psychological, environmental, and sociocultural factors are insufficiently recognized. | High |
Strengths
- Comprehensive historical tracing of fibromyalgia diagnostic criteria from the 16th-century origins through the 1990, 2010, 2011, and 2016 ACR criteria and the newer AAPT proposal.
- Reports concrete validity figures (sensitivity/specificity) and prevalence/sex-ratio differences across criteria and across multiple validated populations (Spanish, Japanese, Iranian, French, Turkish, German, Persian).
- Critically discusses limitations, biases (including sex/gender bias), comorbidity, and the role of biopsychosocial factors rather than simply endorsing one criteria set.
- Highlights emerging objective approaches such as central-sensitization indices (SREP) for future diagnosis.
Limitations
- Narrative review without a systematic search methodology, formal inclusion/exclusion criteria, or quantitative pooling, so it is subject to selection and interpretation bias.
- Validity, prevalence, and sex-ratio figures are drawn from heterogeneous primary studies with differing populations and methods, limiting direct comparability.
- Focused on adults only; the pediatric population is explicitly excluded.
- Newer proposals discussed (e.g., the AAPT dimensional criteria and SREP-based markers) are not yet validated for routine diagnostic use, and the review notes data on their accuracy are still limited.
Key Takeaways for Patients
What This Means for You
Fibromyalgia has no single objective lab test, so diagnosis relies on a clinical assessment of your widespread pain and other symptoms over at least 3 months.
The way fibromyalgia is diagnosed has changed over time, moving away from counting tender points (1990) toward scoring how many body areas hurt plus the severity of symptoms like fatigue, unrefreshing sleep, and brain fog (2010 onward).
Fibromyalgia is not only a women's condition; the review notes the female-to-male ratio looks much higher with older criteria and that men may be under-recognized.
Having fibromyalgia does not rule out other illnesses, and these conditions often occur together, so a diagnosis can be made even when other health problems are present.
Misdiagnosis remains common because many clinicians do not systematically apply the official criteria, so seeking a clinician familiar with current fibromyalgia criteria may help.
Read the Full Paper
Access the complete peer-reviewed study from Journal of Clinical Medicine